Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.
MIAMI and VANCOUVER, BC and BOSTON, Aug. 30, 2021 /PRNewswire/ -- Rapha Capital Management, LLC ("Rapha Capital") today announces it has closed a new convertible note offering totaling US $3 million in three tranches by Rapha Capital BioVentures Fund I, LP ("RCBVFI") to support the clinical development of Imagin Medical Inc.'s (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) ("Imagin" or the "Company") lead product, the i/Blue™ Imaging System. Concurrent with this financing, Kevin Slawin, M.D.» Mehr auf prnewswire.com
Imagin Medical Secures New $3 Million Convertible Note Financing
VANCOUVER, British Columbia, BOSTON and MIAMI, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announces it has closed a new convertible note offering totaling US$3 million in three tranches by Rapha Capital BioVentures Fund I, LP (RCBVFI) to support the clinical development of Imagin's lead product, the i/Blue™ Imaging System. Concurrent with this financing, Kevin Slawin, M.D., a leading urooncologist and manager of the RCBVFI, will join Imagin's board of directors. In addition, with this financing, Imagin is launching its new enhanced website ( https://imaginmedical.com ), which display's the Company's new logo, to reflect the change in energy and direction of the Company.» Mehr auf globenewswire.com
Imagin Medical on Schedule for American Urology Association Demonstration
VANCOUVER, British Columbia, and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reports that the final design of the i/Blue Imaging System™ is on target to be demonstrated at the American Urology Association (AUA) Annual Meeting in September.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Juni 2023 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | −32,04k | - |
Nettoeinkommen | 1,52 Mio | - |
EBITDA | −202,52k | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 10,81 Mio€ |
Anzahl Aktien | 112,76 Mrd |
52 Wochen-Hoch/Tief | 0,0715€ - 0,0000959€ |
Dividenden | Nein |
Beta | 1,08 |
KGV (PE Ratio) | 0,00 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,00 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Imagin Medical Inc. ist ein Unternehmen für chirurgische Bildgebung mit Schwerpunkt auf Blasenkrebs. Das Unternehmen entwickelt das i/Blue Imaging System, um den Bedarf von Urologen an BLC zu decken. Imagin Medical Inc. wurde 1986 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.
Name | Imagin Medical |
CEO | Edward James Hutchens |
Sitz | Vancouver, bc Kanada |
Website | |
Börsengang | 23.01.2013 |
Mitarbeiter | 0 |
Ticker Symbole
Börse | Symbol |
---|---|
Pnk | IMEXF |
Frankfurt | DPD3.F |
München | DPD3.MU |
Assets entdecken
Shareholder von Imagin Medical investieren auch in folgende Assets